Monheim, Germany
April 3, 2009
Active substance
Prothioconazole controls fungi that can harm human health
Over the next two years,
Bayer CropScience AG
will be investing around EUR 30 million in the expansion of
production capacities for the active ingredient prothioconazole
at the Chemical Park in Dormagen. This investment comes in
response to the growing demand in the fungicides business.
Dormagen is one of the biggest Bayer CropScience production
sites in the world.
Prothioconazole is approved in more than 40 countries for use in
cereals, canola, soybeans, pulses and groundnuts. This modern
crop protection substance is marketed globally and provides
outstanding and long-lasting efficacy against a broad spectrum
of plant diseases caused by fungal pathogens. Prothioconazole
also counteracts the formation of mycotoxins, toxic substances
produced by fungi which can harm human health and are a common
cause of food poisoning. In the 2008 financial year, products
based on prothioconazole were among Bayer CropScience’s ten most
important products worldwide, with sales of EUR 246 million.
Bayer is a global enterprise with core competencies in the
fields of health care, nutrition and high-tech materials. Bayer
CropScience AG, a subsidiary of Bayer AG with annual sales of
about EUR 6.4 billion (2008), is one of the world’s leading
innovative crop science companies in the areas of crop
protection, non-agricultural pest control, seeds and plant
biotechnology. The company offers an outstanding range of
products and extensive service backup for modern, sustainable
agriculture and for non-agricultural applications. Bayer
CropScience has a global workforce of more than 18,000 and is
represented in more than 120 countries. |
|
